{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T07:03:21Z","timestamp":1772435001718,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Severe pre-eclampsia is a major contributor to maternal and perinatal morbidity and mortality worldwide. Antihypertensive therapy is essential, yet the impact of the timing of intravenous labetalol initiation on maternal cerebral hemodynamics and clinical outcomes remains uncertain, particularly in Chinese populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective cohort study, we evaluated women with severe pre-eclampsia treated at the Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Jiangsu Province, China, between March 2023 and July 2025. Women diagnosed with severe pre-eclampsia were categorized into two groups based on the timing of labetalol administration: early (\u226460\u202fmin after diagnosis) and late (&amp;gt;60\u202fmin). Clinical characteristics, laboratory data, treatment details, and outcomes were retrieved from electronic records. Primary outcomes were changes in middle cerebral artery pulsatility index (MCA PI) and time to blood pressure control. Secondary outcomes included maternal complications (HELLP syndrome, acute kidney injury, pulmonary edema, intensive care unit admission, and maternal death) and neonatal outcomes (birthweight, small-for-gestational-age, NICU admission, neonatal complications, and perinatal death). Statistical analyses employed Welch\u2019s\n                      <jats:italic>t<\/jats:italic>\n                      -test, Mann\u2013Whitney U test,\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      or Fisher\u2019s exact test, and correlation testing, with\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05 considered significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 372 women screened, 320 were included (162 early-treatment and 158 late-treatment). Baseline demographic and laboratory profiles were comparable. Early labetalol initiation was associated with significantly greater increases in MCA PI at 60\u202fmin, 6\u202fh, and 24\u202fh (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f\u2264\u202f0.040) and with shorter median time to blood pressure control (60 vs. 95\u202fmin,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). At 6 and 24\u202fh, systolic and diastolic pressures were lower in the early group (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.01). Improvement in MCA PI was inversely correlated with time to blood pressure control, suggesting faster hemodynamic stabilization with earlier treatment. Maternal complications and neonatal outcomes did not differ significantly between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early initiation of intravenous labetalol was associated with improved maternal cerebral perfusion and more rapid blood pressure stabilization, without an increase in adverse maternal or neonatal outcomes. These findings highlight the importance of timely antihypertensive therapy in severe pre-eclampsia, although prospective studies are required to establish causality and long-term clinical benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1728192","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:35:18Z","timestamp":1772433318000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of early vs. late administration of labetalol on maternal cerebral perfusion and fetal growth in severe pre-eclampsia"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiahui","family":"Wang","sequence":"first","affiliation":[{"name":"Obstetrics and Gynecology Department, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Yu","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Department, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJMoa1404595","article-title":"Less-tight versus tight control of hypertension in pregnancy","volume":"372","author":"Magee","year":"2015","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/S2214-109X(14)70227-X","article-title":"Global causes of maternal death: a WHO systematic analysis","volume":"2","author":"Say","year":"2014","journal-title":"Lancet Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","article-title":"Pre-eclampsia","volume":"376","author":"Steegers","year":"2010","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"100061","DOI":"10.1016\/j.xagr.2022.100061","article-title":"A comparative analysis of neonatal outcomes in pregnancies complicated by preeclampsia and eclampsia in Ghana","volume":"2","author":"Lawrence","year":"2022","journal-title":"AJOG Glob Rep"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e218401","DOI":"10.1001\/jamanetworkopen.2021.8401","article-title":"Preeclampsia prevalence, risk factors, and pregnancy outcomes in Sweden and China","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1097\/AOG.0000000000003075","article-title":"ACOG Committee Opinion No. 767 Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.preghy.2021.09.008","article-title":"The 2021 International Society for the Study of hypertension in pregnancy classification, diagnosis & management recommendations for international practice","volume":"27","author":"Magee","year":"2022","journal-title":"Pregnancy Hypertens"},{"key":"ref8","volume-title":"WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia: Summary of recommendations (no. WHO\/RHR\/11.30)","year":"2011"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"CD001449","DOI":"10.1002\/14651858.CD001449.pub3","article-title":"Drugs for treatment of very high blood pressure during pregnancy","volume":"7","author":"Duley","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0140-6736(15)00070-7","article-title":"Pre-eclampsia","volume":"387","author":"Mol","year":"2016","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/s0029-7844(03)00475-7","article-title":"Diagnosis and management of gestational hypertension and preeclampsia","volume":"102","author":"Sibai","year":"2003","journal-title":"Obstet Gynecol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"858134","DOI":"10.4061\/2011\/858134","article-title":"Preeclampsia and stroke: risks during and after pregnancy","volume":"2011","author":"Bushnell","year":"2011","journal-title":"Stroke Res Treat"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11906-015-0575-8","article-title":"Cerebrovascular dysfunction in preeclamptic pregnancies","volume":"17","author":"Hammer","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1177\/0271678X18800589","article-title":"The importance of comorbidities in ischemic stroke: impact of hypertension on the cerebral circulation","volume":"38","author":"Cipolla","year":"2018","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.preghy.2021.08.114","article-title":"Cerebral hemodynamics and vasoconstriction in preeclampsia: from diagnosis to resolution","volume":"26","author":"Mart\u00ednez-Mart\u00ednez","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1053\/j.ackd.2013.01.014","article-title":"The management of hypertension in pregnancy","volume":"20","author":"Kattah","year":"2013","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.AOG.0000151116.84113.56","article-title":"Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure","volume":"105","author":"Martin","year":"2005","journal-title":"Obstet Gynecol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/OGX.0000000000000069","article-title":"Long-term consequences of the posterior reversible encephalopathy syndrome in eclampsia and preeclampsia: a review of the obstetric and nonobstetric literature","volume":"69","author":"Postma","year":"2014","journal-title":"Obstet Gynecol Surv"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e0281952","DOI":"10.1371\/journal.pone.0281952","article-title":"Clinical presentation, maternal-fetal, and neonatal outcomes of early-onset versus late onset preeclampsia-eclampsia syndrome in a teaching hospital in a low-resource setting: a retrospective cohort study","volume":"18","author":"Teka","year":"2023","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2478\/amtsb-2020-0015","article-title":"Epidemiology of pregnancy induced hypertension\u2013a multifactorial influence. A retrospective study","volume":"26","author":"Chicea","year":"2021","journal-title":"Acta Med Transilv"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.4103\/0028-3886.241364","article-title":"Posterior reversible encephalopathy syndrome in eclampsia","volume":"66","author":"Garg","year":"2018","journal-title":"Neurol India"},{"key":"ref22","first-page":"28","volume-title":"Severe maternal morbidity in the United States: A primer","author":"Declercq","year":"2021"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ajog.2016.01.154","article-title":"Use of maternal early warning trigger tool reduces maternal morbidity","volume":"214","author":"Shields","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"CD002252","DOI":"10.1002\/14651858.CD002252.pub4","article-title":"Antihypertensive drug therapy for mild to moderate hypertension during pregnancy","volume":"10","author":"Abalos","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/s0140-6736(19)31282-6","article-title":"Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial","volume":"394","author":"Easterling","year":"2019","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1471-0528.2011.03151.x","article-title":"Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial","volume":"119","author":"Raheem","year":"2012","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1053\/j.semperi.2009.02.003","article-title":"Neurologic complications of pre-eclampsia","volume":"33","author":"Zeeman","year":"2009","journal-title":"Semin Perinatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s11011-021-00710-x","article-title":"Neurovascular dysfunctions in hypertensive disorders of pregnancy","volume":"36","author":"Ijomone","year":"2021","journal-title":"Metab Brain Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1097\/AOG.0b013e3182a93fb5","article-title":"Cerebral autoregulation in normal pregnancy and preeclampsia","volume":"122","author":"van Veen","year":"2013","journal-title":"Obstet Gynecol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1067\/mob.2002.125241","article-title":"Cerebral perfusion pressure, and not cerebral blood flow, may be the critical determinant of intracranial injury in preeclampsia: a new hypothesis","volume":"187","author":"Belfort","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.preghy.2019.05.019","article-title":"Preeclampsia postpartum: impairment of cerebral autoregulation and reversible cerebral hyperperfusion","volume":"17","author":"Janzarik","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1053\/j.semperi.2014.08.016","article-title":"Pharmacological management of hypertension in pregnancy","volume":"38","author":"Easterling","year":"2014","journal-title":"Semin Perinatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.mayocp.2018.04.033","article-title":"State-of-the-art diagnosis and treatment of hypertension in pregnancy","volume":"93","author":"Magee","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.placenta.2008.11.009","article-title":"The two stage model of preeclampsia: variations on the theme","volume":"30","author":"Roberts","year":"2009","journal-title":"Placenta"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e035526","DOI":"10.1161\/JAHA.124.035526","article-title":"Association of prepregnancy cardiometabolic health with hypertensive disorders of pregnancy among historically underrepresented groups in the United States","volume":"13","author":"Kwapong","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"ref37","first-page":"45","article-title":"Women friendly health services\u2013a definite step to reduce maternal morbidity and mortality","volume":"49","author":"Kumar","year":"2005","journal-title":"Indian J Public Health"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1728192\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:35:19Z","timestamp":1772433319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1728192\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":37,"alternative-id":["10.3389\/fmed.2026.1728192"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1728192","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"article-number":"1728192"}}